HRA Pharma Signs Deal With PregLem

French drug company HRA Pharma has entered a licensing agreement with Switzerland’s PregLem for the European development and commercialization of HRA Pharma’s ulipristal for the treatment of benign gynecological disorders.

HRA Pharma will retain the rights for development and commercialization of the drug in the rest of the world, the company said.

HRA Pharma has completed a Phase II trial for the drug to treat uterine fibroids. PregLem will develop ulipristal further in this indication by starting a Phase III program in 2008.